1. Academic Validation
  2. Low expression of SGCA promotes lung squamous cell carcinoma malignant progression

Low expression of SGCA promotes lung squamous cell carcinoma malignant progression

  • Sci Rep. 2025 Jul 2;15(1):22578. doi: 10.1038/s41598-025-05312-6.
Guojie Chen # 1 2 Guangyao Mao # 2 Xinyu Zong 3 Xiao Chen 1 Guo Ting 4 Mei Lin 5
Affiliations

Affiliations

  • 1 Medical School of Nantong University, Nantong, 226001, Jiangsu, China.
  • 2 Clinical Laboratory, Affiliated Taizhou People's Hospital of Nanjing Medical University, 399 Hailing South Road, Taizhou, 225300, Jiangsu, China.
  • 3 Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, China.
  • 4 Clinical Laboratory, Affiliated Taizhou People's Hospital of Nanjing Medical University, 399 Hailing South Road, Taizhou, 225300, Jiangsu, China. wangjunguoting2008@163.com.
  • 5 Clinical Laboratory, Affiliated Taizhou People's Hospital of Nanjing Medical University, 399 Hailing South Road, Taizhou, 225300, Jiangsu, China. trylm@ntu.edu.cn.
  • # Contributed equally.
Abstract

Lung squamous cell carcinoma (LUSC) is a common type of non-small-cell lung Cancer with high mortality, lacks effective diagnostic indicators and therapeutic targets. This study aims to reveal that low expression of Alpha-Sarcoglycan (SGCA) promotes LUSC progression and to provide a biomarker for its diagnosis, prognosis evaluation, and targeted therapy. TCGA data and 70 clinical LUSC patients were analyzed. In vitro, H520 and H1703 cells with overexpressed SGCA were transfected with pc-SGCA plasmids, and their proliferation, Apoptosis, and invasion were examined. In vivo, a subcutaneous tumorigenic mouse model was constructed. SGCA was significant in diagnosing LUSC and negatively correlated with T stage. Low SGCA expression enhanced proliferation, invasion, and migration, and inhibited Apoptosis. Overexpression of SGCA inhibited tumor growth in mice. Low expression of SGCA is closely associated with LUSC progression, making it a potential prognostic factor and therapeutic target for LUSC.

Keywords

Alpha-sarcoglycan; Clinical; Diagnosis; Lung squamous cell carcinoma; Prognosis.

Figures
Products